NorthWest Biotherapeutics Inc (NWBO)

[beachhyena]

I am beginning to see the light with regard to the crumbs Tilt has pointed to.

From the 10Q.

Recent Issued Accounting Pronouncements

Compensation-Stock Compensation

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the condensed consolidated financial statements and disclosures, but does not expect it to have a significant impact.

For all here is a breakdown of what this really means in a nutshell.

http://www.ey.com/publication/vwluassetsdld/tothepoint_03149-171us_modificationsbp_11may2017/$file/tothepoint_03149-171us_modificationsbp_11may2017.pdf?OpenElement

A merger with Cognate and new stock symbol would be something to behold at this point.